Zai Lab announces global clinical trial collaboration and supply agreement to evaluate novel DLL3 ADC, Zocilurtatug Pelitecan, in combination with a bispecific T-cell Engager therapy

CAR-T Digest - August 2020

Weekly Digest - April 2026

01 April 2026: Zai Lab announces global clinical trial collaboration and supply agreement to evaluate novel DLL3 ADC, Zocilurtatug Pelitecan, in combination with a bispecific T-cell Engager therapy

Zai Lab has entered into a global clinical trial collaboration with Amgen to evaluate its DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen’s T-cell engager IMDELLTRA in patients with extensive-stage small cell lung cancer
Under the agreement, Amgen will sponsor a global Phase 1b study to evaluate the safety and efficacy of the combination, with Zai Lab retaining full ownership of the ADC
The combination will be evaluated in extensive-stage SCLC, where patients often relapse after platinum-based therapy and have limited treatment options
Zocilurtatug pelitecan is a DLL3-targeting ADC with a topoisomerase I inhibitor payload, while IMDELLTRA engages T-cells against DLL3-expressing tumor cells, enabling a coordinated cytotoxic and immune-mediated approach
Early clinical data with the ADC demonstrated high response rates, intracranial activity, and manageable safety in heavily pretreated SCLC, supporting further evaluation in combination strategies